---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-009935"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:50:48.542241+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Processa Pharma FY2022 net loss $27.4M; cash raised to $12.9M; NGC-Cap Phase 2B to start H2 2023

## Summary
- Net loss for year ended Dec 31, 2022 was $27.4M ($1.70 per share) vs $11.4M ($0.75) in 2021, including $7.3M non-cash intangible impairment.
- Cash of $6.5M at year-end; subsequently raised $6.4M net from registered direct offering, total $12.9M expected to fund operations into Q3 2024.
- R&D expenses $11.5M (2022) vs $6.9M (2021); G&A $8.8M vs $4.7M, driven by stock-based comp and trial costs.
- FDA meeting in mid-April to discuss Next Generation Capecitabine Phase 2B trial; initiation expected H2 2023 in colorectal cancer.
- Dose escalations for NGC-Cap continue with no adverse events; Phase 2A gastroparesis trial completed, out-licensing for non-oncology assets.

## SEC filing metadata
- accession: 0001493152-23-009935
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315223009935/0001493152-23-009935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315223009935/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-009935
- JSON: https://secwatch.observer/filing/0001493152-23-009935.json
- Plain text: https://secwatch.observer/filing/0001493152-23-009935.txt

## Key facts
- Earnings Releases
  Processa Pharmaceuticals, Inc. reported year ended December 31, 2022 results: net income $27.4 million, or $1.70 per share, EPS $1.70 per share.
  - Period: year ended December 31, 2022
  - Net income: $27.4 million, or $1.70 per share
  - EPS: $1.70 per share
  - Result: reported results
  source text: Our net loss for the year ended December 31, 2022 was $27.4 million, or $1.70 per share, compared to a net loss of $11.4 million, or $0.75 per share for the same period of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533743/000149315223009935/0001493152-23-009935-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.